Biosensors and Bioelectronics

Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics

Retrieved on: 
Friday, March 24, 2023
Yale University, Mitochondrion, PTC Therapeutics, Drug development, University, Gene, The Conference Board, Conference call, PTC, Cancer, Eladocagene exuparvovec, Coronavirus Scientific Advisory Board, European Research Advisory Board, Brain, CMO, RNA, History, CNS, DSM-IV codes, EMA, Bachelor of Arts in Clinical Psychology, Biosensors and Bioelectronics, Shriners Hospitals for Children, ET, Retirement, Oxidative stress, Consultant, Patient, University of Washington Department of Global Health, Stuart, Growth, Mitochondrial disease, Rare, Therapy, Scientific Advisory Group for Emergencies, Conference, Stu, Management, Pharmaceutical industry, Vaccine, Nursing

SOUTH PLAINFIELD, N.J., March 24, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT). Stuart Peltz, Ph.D., founding Chief Executive Officer (CEO) of PTC Therapeutics announced today that he is stepping down after 25 years. Dr. Peltz has led PTC Therapeutics as its CEO since its founding in 1998 and pioneered the field of RNA-directed drug development. Under his leadership, PTC has grown from a research organization with expertise in the control of RNA processes to a publicly traded, integrated, global biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for the treatment of neurological and neuromuscular disorders, metabolic disorders, and cancer.

Key Points: 
  • Stuart Peltz, Ph.D., founding Chief Executive Officer (CEO) of PTC Therapeutics announced today that he is stepping down after 25 years.
  • Dr. Peltz has led PTC Therapeutics as its CEO since its founding in 1998 and pioneered the field of RNA-directed drug development.
  • What Stuart and the team have achieved in 25 years is extraordinary," said Michael Schmertzler, Chairman of the Board of Directors.
  • Matthew Klein, M.D., M.S., F.A.C.S., current Chief Operating Officer, has been named the company's CEO and will join the Board of Directors.

GlucoModicum publishes first-in-human data assessing the safety and effectiveness of its MHD technology for accurate needle-free glucose monitoring

Retrieved on: 
Wednesday, November 9, 2022
Biosensors and Bioelectronics, Nature Research, CBG, Medtech, Glucose meter, Research, Adoption, Technology, Nature, Glucose, Safety, Human, MHD, Skin, CGM, MARD, Scientific Reports, Talisman, ISF, Medical imaging

Data drawn from glucose tolerance tests on healthy volunteers obtained a strong correlation between the concentration of glucose in interstitial fluid (ISF) samples extracted with GlucoModicums MHD technology against capillary blood glucose (CBG) samples.

Key Points: 
  • Data drawn from glucose tolerance tests on healthy volunteers obtained a strong correlation between the concentration of glucose in interstitial fluid (ISF) samples extracted with GlucoModicums MHD technology against capillary blood glucose (CBG) samples.
  • The data obtained with MHD technology demonstrate a 12.9% MARD (Mean Absolute Relative Difference), a measure of the agreement between a glucose sensor reading and a reference blood glucose reading.
  • This provides a strong evidence base supporting the development of a non-invasive glucose monitor using GlucoModicums MHD platform technology.
  • www.glucomodicum.com
    GlucoModicums magnetohydrodynamic (MHD) technology is currently being productized as the Talisman, the first new, truly non-invasive CGM technology in 25 years.

GlucoModicum publishes data showing integration of MHD technology with ultra-sensitive biosensor enables accurate needle-free glucose monitoring

Retrieved on: 
Tuesday, April 5, 2022
Patient, Skin, CGM, University, Solution, Biosensors and Bioelectronics, University of Helsinki, Amperometry, Technology, Diabetes, The Journal, Bioelectronics, MHD, Health, Medical device, Medical imaging

Helsinki, Finland, 5 April 2022 GlucoModicum, a company transforming glucose monitoring with precise, needle-free magnetohydrodynamic technology, announced today that peer-reviewed data showing the effective integration of the Companys magnetohydrodynamic (MHD) technology platform with an amperometric biosensor has been published in the journal Biosensors and Bioelectronics .

Key Points: 
  • Helsinki, Finland, 5 April 2022 GlucoModicum, a company transforming glucose monitoring with precise, needle-free magnetohydrodynamic technology, announced today that peer-reviewed data showing the effective integration of the Companys magnetohydrodynamic (MHD) technology platform with an amperometric biosensor has been published in the journal Biosensors and Bioelectronics .
  • GlucoModicums MHD fluid extractor was integrated with an amperometric glucose biosensor to determine the efficacy of a continuous non-invasive glucose monitoring (CGM) device designed to measure glucose levels through the skin.
  • Combining previous data with the findings from this study, GlucoModicums novel method of precise, needle-free glucose monitoring is demonstrated to be safe and scientifically sound.
  • GlucoModicum is a company transforming glucose monitoring with precise, needle-free magnetohydrodynamic technology.

Chung-Ang University Researchers Show A Gold-Paved Path Towards Faster COVID-19 Diagnosis

Retrieved on: 
Friday, January 21, 2022
PCR, Patient, RT, RNA, COVID-19, Severe acute respiratory syndrome coronavirus 2, RNA polymerase II, Gene, Disease, DNA, Infection, SERS, Motivation, Diagnosis, Epidemic, RNA-dependent RNA polymerase, Biosensors and Bioelectronics, Vaccine

The current standard for COVID-19 diagnosis is reverse transcriptase-polymerase chain reaction (RT-PCR), a technique in which viral genes are detected after they undergo multiples cycles of amplification.

Key Points: 
  • The current standard for COVID-19 diagnosis is reverse transcriptase-polymerase chain reaction (RT-PCR), a technique in which viral genes are detected after they undergo multiples cycles of amplification.
  • However, this technique is time-consuming, creating a testing backlog across diagnostic centers and leading to delayed diagnoses.
  • In a recent study published in Biosensors and Bioelectronics , researchers from Korea and China have introduced a novel nanotechnology-based platform that can shorten the time required for COVID-19 diagnosis.
  • Based on this previous discovery, Prof. Choo and his team developed the novel SERS-PCR platform for COVID-19 diagnosis.

Feinstein Institutes Bioelectronic Medicine Scientists Develop First-of-its-Kind Wireless Neuromodulation Device for Research

Retrieved on: 
Wednesday, January 19, 2022
Medical Devices, Health, Clinical Trials, Research, Science, Biotechnology, Medicine, Feinstein Institute for Medical Research, Electricity, Credit, Research, Technology, Patient, LinkedIn, Inflammation, Outline, Science, Bioelectronics, Vagus nerve, CEO, Autoimmunity, Medical research, Disease, Mental health, Oxygen, Electrode, Â, VNS, Nervous system, Northwell Health, Heart failure, Molecular medicine, Method, Mouse, Feinstein, Genetics, Environment, Doctor of Philosophy, Multimedia, Cancer, Rheumatoid arthritis, Engineering, Brain, Heart rate, Biosensors and Bioelectronics, Conditional sentence, Institute, Medical device, Pharmaceutical industry, MD

View the full release here: https://www.businesswire.com/news/home/20220119005185/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220119005185/en/
    Pictured is a second generation version of the wireless neuromodulation implantable mouse stimulator developed at the Feinstein Institutes.
  • (Credit: Feinstein Institutes)
    Bioelectronic medicine is a new approach to treating and diagnosing disease and injury that has emerged from the Feinstein Institutes labs.
  • The teams research builds off previous studies unveiled by the Feinstein Institutes the global scientific home of bioelectronic medicine.
  • Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine.

Global Biosensors Market Size, Share & Trends Analysis Report 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 20, 2021
Health, Biotechnology, Health, Medicine, Biosensors, Clinical medicine, Biosensors and Bioelectronics, Blood glucose monitoring, Diabetes, Food and Drug Administration

b'The "Biosensors Market Size, Share & Trends Analysis Report by Application by Technology, by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global biosensors market size is anticipated to reach USD 41.8 billion by 2028 and is expected to expand at a CAGR of 7.9% from 2021 to 2028.\nThe rising prevalence of chronic conditions such as diabetes and obesity and the growing demand for early and accurate detection of any associated condition are the key driving factors for the market.\nFurthermore, the outbreak of COVID-19 has drastically spurred the demand for point-of-care testing devices.

Key Points: 
  • b'The "Biosensors Market Size, Share & Trends Analysis Report by Application by Technology, by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global biosensors market size is anticipated to reach USD 41.8 billion by 2028 and is expected to expand at a CAGR of 7.9% from 2021 to 2028.\nThe rising prevalence of chronic conditions such as diabetes and obesity and the growing demand for early and accurate detection of any associated condition are the key driving factors for the market.\nFurthermore, the outbreak of COVID-19 has drastically spurred the demand for point-of-care testing devices.
  • FDA is giving fast-track approvals to the companies owing to the shortage of these devices globally.\nFor instance, in May 2020, Philips secured 510k FDA clearance for its wearable biosensor, which helps in managing confirmed and suspected cases of COVID-19 in hospitals, promoting biosensors technology and product development.\nMoreover, rapid technological advancements are expected to be a significant factor for market growth over the forecast period.
  • For instance, in June 2020, Abbott received the U.S. FDA clearance for its next-generation, integrated glucose monitor system- FreeStyle Libre 2 intended to measure diabetes in individuals aged 4 years and above and has an optional real-time alarm.\nOn the basis of application, the medical segment dominated the market in 2020 with a revenue share of 66.6%.
  • The device is considered an essential tool in the detection and monitoring of a wide range of medical conditions, such as diabetes and cancer.\nBased on technology, the electrochemical segment dominated the market in 2020 with a revenue share of 70.9% owing to its widespread applications for analysis in biochemical and biological processes.\nThe home healthcare diagnostics segment is expected to witness the fastest growth rate over the forecast period owing to the high prevalence of chronic disease globally.\nNorth America dominated the market in 2020 with a revenue share of 39.9% owing to the presence of a highly developed healthcare infrastructure and favorable reimbursement policies in this region.\nChapter 3 Biosensors Market Variables, Trends & Scope\n'

Infostretch Expands Digital Health Business

Retrieved on: 
Tuesday, July 28, 2020
Data management, Health, Technology, Software, General Health, Biotechnology, Articles, Health informatics, Technology, Science and technology, Digital health, Telehealth, Digital native, eHealth, Biosensors and Bioelectronics

Infostretch has expanded its digital health business with the addition of five new customers intending to digitally disrupt the healthcare market, including Cala Health, J. Knipper, Willow and Navigating Cancer.

Key Points: 
  • Infostretch has expanded its digital health business with the addition of five new customers intending to digitally disrupt the healthcare market, including Cala Health, J. Knipper, Willow and Navigating Cancer.
  • Infostretch works with one of the largest integrated managed care consortia in the United States and has been involved in major healthcare digital engineering initiatives including digital medicine, telehealth and wearable biosensors.
  • Infostretch has worked with start-ups and large corporations, from digital natives to traditional incumbents, and we have yet to meet a company thats not facing disruption from digital, commented Rutesh Shah, CEO and Founder of Infostretch.
  • Infostretch is a pure-play digital engineering services firm focused on helping companies accelerate their digital initiatives from strategy and planning through execution.